July 15, 2015.
Celgene Corporation (Summit, NJ) has announced that it is to acquire biopharmaceutical firm Receptos, Inc. (San Diego, CA) in a deal that will "significantly enhance" Celgene’s Inflammation & Immunology (I&I) portfolio and build on it growing expertise in inflammatory bowel disease (IBD), the cpmpany reports.
The transaction adds Receptor's Ozanimod, which has demonstrated areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), to Celgene’s pipeline.
Bob Hugin, Chairman and Chief Executive Officer of Celgene, commented: "The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas." The deal will power Celegene's I&I franchise towards a revised long-term, 2020 target to exceed $4.0 billion, up from its previous target of $3.0 billion.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.